Skip to main content
An official website of the European Union An official EU website
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

A novel generation of skin substitutes to clinically treat a broad spectrum of severe skin defects

Objective

Large full-thickness skin defects resulting from burns, soft tissue trauma, congenital giant nevi, tumour resection, and disease leading to skin necrosis, represent a significant and common clinical problem worldwide. This problem is far from being solved. The main challenge encountered is that most autologous skin grafting techniques are based on transplanting split-thickness skin (the today’s gold standard). Split-thickness skin contains all of the epidermis, but only remnants of the dermis. This lack of dermal tissue, frequently leads to significant scarring. Consequently, a true dermal substitute is required, which instantly exerts the cell-instructive properties of a neo-dermis. The partners of EuroSkinGraft can now offer 2 dermal substitutes, Novomaix and denovoDerm, plus the dermo-epidermal skin substitute denovoSkin. The development of all 3 substitutes was significantly supported by the FP6-program (EuroSTEC). The envisaged clinical studies are aiming strictly at a one-step surgical procedure (instead of the common two-step procedure, using Integra Artificial Skin).This is to be reached with the following protocol:
Clinical application of Novomaix
1. Experimental arm 1: split-thickness skin on Novomaix applied on full-thickness wounds
2. Reference arm 1: split-thickness skin applied directly on the wound bed
Clinical application of denovoDerm
1. Experimental arm 1: split-thickness skin on denovoDerm applied on full-thickness wounds
2. Reference arm 1: split-thickness skin applied directly on the wound bed
Clinical application of denovoSkin
1. Experimental arm 1: denovoSkin applied on full-thickness wounds
2. Reference arm 1: split-thickness skin applied directly on the wound bed
The strength of this project lies in: the high degree to which real regenerative medicine is translated into the clinic, the innovative and highly functional character of the 3 products to be tested, the central contribution of the 3 SMEs, and the excellence of the 3 clinics.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Call for proposal

FP7-HEALTH-2011-two-stage
See other projects for this call

Coordinator

UNIVERSITAT ZURICH
EU contribution
€ 3 020 144,34
Address
RAMISTRASSE 71
8006 Zurich
Switzerland

See on map

Region
Schweiz/Suisse/Svizzera Zürich Zürich
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Participants (9)

My booklet 0 0